Novo Nordisk Announces Commercial Availability of Saxenda® in U.S.

Published in June 2015 Issue             

Novo Nordisk announced that Saxenda® (liraglutide [rDNA origin] injection) is now available commercially in the United States. Saxenda is the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults.

The U.S. Food and Drug Administration approved Saxenda in December 2014 as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. It is indicated for use in adults with a body mass index (BMI) of 30 or greater (obesity) or adults with a BMI of 27 or greater (overweight) who have at least one weight-related condition such as hypertension, type 2 diabetes, or high cholesterol.

In a company press release, Jesper Hoiland, President of Novo Nordisk Inc. said, "Novo Nordisk is pleased to offer a new treatment that can provide some patients who have obesity or are overweight with comorbidities a new path to achieving clinically meaningful weight loss.”

According to the release, clinical trial data showed that Saxenda, in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss in some patients than reduced-calorie diet and physical activity alone.

“Saxenda can provide an additional therapy for some patients who have not been successful in losing weight with diet and exercise alone,” said John M. Morton, MD, MPH, FACS, ASMBS President and Chief, Bariatric and Minimally Invasive Surgery, Stanford University School of Medicine. “There will likely be some application before and after bariatric surgery in helping some patients with their weight loss. It is interesting to note how current pharmacological interventions are patterned after physiologic processes discovered through bariatric surgery. We anticipate further elaboration of the obesity continuum of care through medications like Saxenda.”